Thyroid eye disease (TED) therapy Tepezza – the top asset in Amgen's $26 billion takeover of Horizon in 2023 – could be facing competition from an easier-to-dose alternative from Sling ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Modifiable risk factors for thyroid eye disease include smoking habits and patient endocrine status. Avoid treating patients with active TED with radioactive iodine ablation. KOLOA, Hawaii ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Thyroid eye disease, which causes inflammation and damage to the tissues surrounding the eye, affects an estimated 90 to 300 people per 100,000 in the U.S. Viridian confirmed that it remains on ...

KOLOA, Hawaii — Effective management of thyroid eye disease requires a focus on mitigating modifiable risk factors, according to a presenter at Hawaiian Eye 2025. Linsitinib, an oral small ...

Out-licensing its greater-China anti-IGF-1R thyroid eye disease programs to Zai Lab provides immediate financial benefits and potential future royalties, enhancing the company's strategic ...